SUPERNUS PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.03 million shares for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2020-05-15
- SUPERNUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2020-03-31 was 3.03M shares, a 398.25% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2019-03-31 was 608.95K shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month |
|---|---|
| 2020-03-31 | 3.03M shares 10-Q · filed 2020-05-15 |
| 2019-03-31 | 608.95K shares 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |